NanoVibronix Signs Term Sheet With Apogepha for Europe Distribution of UroShield Urology Therapy Device

MT Newswires10/09 21:10

NanoVibronix 2Q Rev $817,000 >NAOV

Dow Jones08/21 20:34

NanoVibronix Highlights 2Q Rev Growth and Narrowing of Loss From Ops in Letter to Stockholders

Dow Jones08/21 20:31

NanoVibronix Second Quarter 2024 Earnings: US$0.25 Loss per Share (Vs US$0.65 Loss in 2Q 2023)

Yahoo Finance08/17 20:54

ナノ ビブロ | 10-Q：Q2 2024 四半期報告書

SEC08/15 04:07

NanoVibronix Announces Commencement of UroShield Clinical Study at the University of Michigan

Business Wire05/22 20:30